AEGLEA Trademark

Trademark Overview


On Wednesday, August 26, 2020, a trademark application was filed for AEGLEA with the United States Patent and Trademark Office. The USPTO has given the AEGLEA trademark a serial number of 90138790. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 3, 2024. This trademark is owned by Aeglea BioTherapeutics, Inc.. The AEGLEA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious disea...

Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics, all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments, and all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; Design, engineering, research, development and testin...
aeglea

General Information


Serial Number90138790
Word MarkAEGLEA
Filing DateWednesday, August 26, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 7, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria
Goods and ServicesScientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics, all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments, and all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; Design, engineering, research, development and testing services, all for medical research purposes in the fields of cancer, rare genetic disease, Arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 29, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 29, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAeglea BioTherapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAustin, TX 78746

Party NameAeglea BioTherapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAustin, TX 78746

Trademark Events


Event DateEvent Description
Saturday, August 29, 2020NEW APPLICATION ENTERED
Tuesday, September 29, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 24, 2020ASSIGNED TO EXAMINER
Wednesday, June 30, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 31, 2020NON-FINAL ACTION WRITTEN
Thursday, December 31, 2020NON-FINAL ACTION E-MAILED
Thursday, December 31, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 29, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 29, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, July 31, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 7, 2021PUBLISHED FOR OPPOSITION
Wednesday, August 18, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 7, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, April 29, 2022SOU TEAS EXTENSION RECEIVED
Friday, April 29, 2022SOU EXTENSION 1 FILED
Friday, April 29, 2022SOU EXTENSION 1 GRANTED
Tuesday, November 1, 2022SOU EXTENSION 2 GRANTED
Tuesday, May 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 1, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, November 1, 2022SOU EXTENSION 2 FILED
Thursday, November 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 1, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 2, 2023SOU EXTENSION 4 FILED
Monday, May 1, 2023SOU EXTENSION 3 FILED
Monday, May 1, 2023SOU EXTENSION 3 GRANTED
Wednesday, May 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 2, 2023SOU TEAS EXTENSION RECEIVED
Thursday, November 2, 2023SOU EXTENSION 4 GRANTED
Saturday, November 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 3, 2024ABANDONMENT - NO USE STATEMENT FILED
Thursday, May 16, 2024ASSIGNED TO EXAMINER
Friday, July 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED